New! Cor.4U® Human iPS Cell-Derived Cardiomyocytes
Axiogenesis AG has launched the Cor.4U® human induced pluripotent stem (iPS) cell-derived cardiomyocyte product line for use in testing the efficacy and safety of pharmaceutical therapies. Succeeding its flagship products, Cor.At® mouse ESC and iPSC derived cardiomyocytes (now marketed by Sigma Aldrich), Cor.4U® human iPS cell-derived cardiomyocytes are a result of the combined expertise of Shinya Yamanaka's Nobel Prize winning iPS cell technology with Axiogenesis' proprietary production technology. These technologies enable the commercialization of pure in vitro differentiated human cardiomyocytes of premium quality, consistency and purity. Learn more about Cor.4U®.
Cor.4U® iPS cell-derived cardiomyocytes have been validated in various applications including manual and automated Patch Clamp, Microelectrode Arrays (MEA), and xCELLigence Cardio. To request datasets and protocols, contact us.
As a pioneer of stem cell technology and the world leader in murine stem cell-derived products, Axiogenesis also offers pure in vitro differentiated smooth muscle cells (Smac.4M®) and endothelial cells (Endo.4M®), both available by Sigma Aldrich.
In addition to cell line products, Axiogenesis offers a unique service portfolio for in vitro toxicology and drug discovery. Axiogenesis provides assays in electrophysiology (Cor.At Mel.Cor; Cor.4U Mel.Cor), cardiotoxicity (Cor.At and Cor.4U CardioEffect Screening, Cor.At Tox) and embryotoxicity, as well as a proprietary in vitro disease model for cardiac hypertrophy.